학술논문
International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology
Document Type
Article
Author
Nangaku, Masaomi; Kitching, A. Richard; Boor, Peter; Fornoni, Alessia; Floege, Jürgen; Coates, P. Toby; Himmelfarb, Jonathan; Lennon, Rachel; Anders, Hans-Joachim; Humphreys, Benjamin D.; Caskey, Fergus J.; Fogo, Agnes B.; Angeletti, Andrea; Bedard, Patricia W.; Benigni, Ariela; Granqvist, Anna Björnson; Chabova, Vera Certikova; Chatziantoniou, Christos; Cross, Jennifer; Damster, Sandrine; Donner, Jo-Ann; Eitner, Frank; Faguer, Stanislas; Fontanella, Antonio; Fujimoto, Yuri; Gaut, Joseph; Gewin, Leslie; Hansen, Pernille B.L.; He, John Cijiang; Hughes, Jeremy; Inagi, Reiko; Jenkinson, Celia; Jha, Vivekanand; Kato, Mikio; Kelly, Darren; Kopp, Jeffrey; Korstanje, Ron; Mačiulaitis, Romaldas; Mark, Patrick B.; Marti, Hans-Peter; McAdoo, Stephen P.; Miner, Jeffrey H.; Ortiz, Alberto; Parikh, Samir M.; Pozzi, Ambra; Romagnani, Paola; Ronco, Pierre; Rovin, Brad H.; Saez-Rodriguez, Julio; Saleem, Moin A.; Sayer, John A.; Shankland, Stuart; Shaw, Andrey S.; Suzuki, Yusuke; Takano, Tomoko; Tang, Sydney; Tolba, Rene; Viel, John; Yamada, Yoshihisa; Yanagita, Motoko; Yokoo, Takashi; Yoshida, Nobuya; Yuen, Darren; Zent, Roy; Zhang, Aihua
Source
Kidney International; July 2023, Vol. 104 Issue: 1 p36-45, 10p
Subject
Language
ISSN
00852538; 15231755
Abstract
Preclinical tests in animal models are key steps in early drug development. Consequently, the International Society of Nephrology held a consensus meeting that connected experts in the global kidney community in order to provide guidance on optimal management of translational animal studies for the development of new drugs to treat kidney disease, entitled “TRANSFORM; TRAnslational Nephrology Science FOR new Medications.” The meeting covered various themes, including the following: (i) selection of disease model; (ii) pharmacokinetics; (iii) interventions in late preclinical models; (iv) choice of animal; (v) statistical power; (vi) organoids and organ-on-a-chip models; and (vii) reporting of results. This guidance is the first to be provided on the optimal conduct of translational animal studies for the development of new drugs to treat kidney disease. These recommendations are designed to accelerate development of new drugs for efficacious treatment of kidney diseases, and to improve the prognosis and quality of life of patients with a variety of kidney diseases.